A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of TJ0113 Capsules Administered Orally as Single Dose, Multiple Doses, and Doses in the Fed State in Healthy Subjects
Latest Information Update: 11 Feb 2026
At a glance
- Drugs TJ 0113 (Primary)
- Indications Depressive disorders; Hereditary nephritis; Parkinson's disease
- Focus Adverse reactions
- Sponsors Hangzhou PhecdaMed
Most Recent Events
- 11 Feb 2026 New trial record